Compound 11 is a potent and highly selective antagonist suitable for further investigations of the role of the kinin B 1 R in models of inflammation, pain and sepsis based on the rabbit.
Introduction
The kinin B 1 receptor (B 1 R) is a G protein coupled receptor selectively stimulated by sequences related to bradykinin (BK), but not by BK itself. Instead, des-Arg 9 -BK, Lys-BK (kallidin) and Lys-des-Arg 9 -BK (des-Arg 10 -kallidin) stimulate the human and rabbit recombinant B 1 Rs, the last peptide with the highest affinity (Menke et al., 1994; MacNeil et al., 1995) . The B 1 R is also strongly regulated by inflammatory conditions, to the point of being largely inducible in several experimental systems (Marceau et al., 1998) . The kinin B 1 R, expressed by vascular and epithelial cells, fibroblasts, some leukocytes and sensory and other neurons (Marceau et al., 1998; Christiansen et al., 2002; Ricupero et al., 2000; Shughrue et al., 2003) , has attracted the interest of medicinal chemists as a therapeutic target because this molecule is involved in sustained inflammation and inflammatory pain perception (Perkins et al., 1993; Fox et al., 2003; Su et al., 2003) .
The regulation of the B 1 R at the cell level has revealed a number of findings of interest.
Experimental results support a role of inflammatory cytokines and nuclear factor-κB in B 1 R induction (Ni et al., 1998; Schanstra et al., 1998; Sabourin et al., 2002b; Passos et al., 2004) . In systems where the B 1 R expression is inducible over a ~2-6 h period by cytokine treatment or tissue injury, protein synthesis inhibitors prevent its surface expression and function (Marceau et al., 1998; Fortin et al., 2003b) . Radioligand binding and phosphate labeling have shown that the B 1 R neither is subjected to important agonist-induced endocytosis nor phosphorylated, unlike the related BK B 2 receptor (B 2 R) (Faussner et al., 1998; Blaukat et al., 1999) . Agonist-induced cellular redistribution has been studied using a fusion protein composed of the rabbit B 1 R fused with the yellow fluorescent protein (YFP). Lys-des-Arg 9 -BK induces a condensation of cell surface B 1 R-YFP into aggregates that remain associated with the plasma membrane and that were This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from identified as cholesterol rich rafts; this redistribution was slowly reversible on washing at 37°C, and distinct from endocytosis (Sabourin et al., 2002a) . Finally, it has been proposed that the rapidly induced B 1 R is subjected to an accelerated cellular degradation when its synthesis subsides in cellular models (Fortin et al., 2003b) . This mechanism, based on a form of agonistindependent endocytosis, could contribute to terminate B 1 R signaling as the inflammatory condition is being resolved.
Several nonpeptide antagonists of the parent BK B 2 R have been discovered over the last decade (Pruneau et al., 1999; Dziadulewicz et al., 2000; with proposed applications in inflammatory pain and the prevention of vasogenic edema of the brain (Burgess et al., 2000; Kaplanski et al., 2002; Zausinger et al., 2002) . -BK binding to the rabbit recombinant B 1 R expressed in CHO cells was reportedly 50 pM (Su et al., 2003) . SSR240612 is another example on non-peptide B 1 R agonist with significant structural similarity to Compound 11 (Gougat et al., 2004) . The characterization of low molecular weight and cell-permeant nonpeptide antagonists for both types of kinin receptors opens new experimental possibilities, by comparison with the previously available peptide antagonists.
We have verified the potency and specificity of Compound 11 for several effects mediated by the rabbit B 1 R. Further, we have studied the possibility that this nonpeptide kinin receptor antagonist alters the surface expression of the B 1 R. , a peptide and a nonpeptide B 2 R antagonist . The nonpeptide B 2 R antagonist bradyzide (Dziadulewicz et al., 2000; Burgess et al., 2000) is a gift from Dr. E. Dziadulewizc (Novartis, London). Losartan, a nonpeptide antagonist of the angiotensin II (Ang II) AT 1 receptor (AT 1 R), and Compound 11 (2-{( Contractility studies. A local ethics committee approved the procedures based on rabbits. Rabbit aortic rings (New Zealand white, 1.5-2 kg, Charles River, St. Constant, Canada) were suspended under a tension of 2 g in 5 ml tissue baths containing oxygenated (95% O 2 : 5% CO 2 ) and warmed (37°C) Krebs solution as described . Some experiments were also This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from performed on rabbit jugular veins, cut into 2 cm strips and suspended under a tension of 1 g in 5 ml tissue baths containing oxygenated and warmed Krebs solution to which 1 µM captopril was added and rings of mesenteric arteries (suspended under a tension of 1 g, Petitclerc et al., 1994) .
Contractility studies in the aortic preparation were based upon the construction of cumulative concentration-responses curves for des-Arg 9 -BK (a B 1 R agonist on this tissue) and an additional one for Ang II (an AT 1 R agonist in the aorta; Fortin et al., 2003a) . These studies aimed to investigate the potency, surmountability and specificity of the B 1 receptor antagonist in the vascular smooth muscle preparation. In each tissue, two cumulative concentration-response curves for des-Arg 9 -BK were constructed at times 3.5 and 5.5 h from the beginning of the incubation of the preparation. Compound 11 or its DMSO vehicle in control tissues, was introduced at time 5 h and maintained in the bathing fluid during the construction of the second curve (effect of the antagonist at 5.5 h). An additional cumulative concentration-response curve for Ang II was constructed in some tissues at time 7.5 h in tissues re-exposed to Compound 11 or the DMSO vehicle at time 7 h. In different sets of tissues, two concentration-response curves were constructed at times 3.5 and 5.5 h for des-Arg 9 -BK and Lys-des-Arg 9 -BK, respectively, to calculate the potency of Compound 11 (applied at time 5 h) against the latter high affinity B 1 R agonist. Contractility results were expressed as a percent of the maximal response recorded in each tissue when constructing the 5.5 or 7.5 h curves.
The contractility experiments in the rabbit jugular vein, which responds to kinins via B 2 Rs and histamine via H 1 receptors, were performed to investigate the specificity of the recently produced B 1 R antagonist (as in Larrivée et al., 2000) . Two cumulative concentration-response curves for (Churchill and Ward, 1986; Deblois and Marceau, 1987) . Compound 11 or one of isoform-specific cyclooxygenase (COX)
inhibitors were introduced 30 min before the phenylephrine stimulation used to induce tissue precontraction in order to analyze the mechanism of action of des-Arg 9 -BK.
Construction of the rabbit myc-B 1 receptor conjugate (myc-B 1 R). In order to assess the abundance of kinin receptors at the cell surface in a radioligand-independent manner, we produced and characterized a rabbit B 1 R labeled with the N-terminal (extracellular) myc epitope.
Using the pCDNA3-based vector for the wild type rabbit B 1 R as a template, the coding region of the B 1 R gene was amplified by polymerase chain reaction (PCR). ). The assay was performed as described using 75 cm 2 flasks of serum-starved (24 h) cells (Fortin et al., 2003c) . The 9e10 monoclonal antibodies or the alternate anti-myc monoclonal 4A6
(Upstate, Charlottesville, VA) were applied to the immunoblot of myc-B 1 R (dilution 1:1000-1:500) using the same general methods. Membranes were prepared from 75 cm 2 flasks of HEK 293 cells transiently expressing myc-B 1 R or of untransfected cells as described and submitted to electrophoresis (50 µg protein per track) followed by transfer and immunoblotting.
Data analysis. When applicable, numerical values are means ± s.e.m. The parameters of the Scatchard (binding saturation data) and Shild (antagonist potency) plots were calculated using a computer program (Tallarida and Murray, 1987) .
This article has not been copyedited and formatted. The final version may differ from this version. residual relaxing effect 6.3 ± 6.3%, n = 2, P < 0.01 by Dunnett's test), without influencing the action of the agent used to induce the precontraction (the α-adrenoceptor agonist phenylephrine; fig. 3B ). The relaxing effect of the kinin is mediated by PGs in this system (Churchill and Ward, 1986 ), but the relevant COX isoform coupled to B 1 R mediation has not been determined. The COX-1 and -2 isoform-selective inhibitors SC-560 and NS-398 both attenuated the relaxing effect of des-Arg 9 -BK (residual relaxing effect of 5.82 ± 5.8 and 0.1 ± 8.3, respectively, n = 3,
P<0.01 for both values by Dunnett's test) (fig. 3C, D). The precontracted mesenteric artery rings
were relaxed by the PGI 2 mimetic drug iloprost ( fig. 3E ). Some precontracted tissues were exposed to Compound 11 when the full relaxing effect of des-Arg 9 -BK was obtained ( fig. 3F ):
before reversing the relaxation and regaining the plateau tension, tissues were transiently further relaxed in the minutes following the application of the B 1 R antagonist (observed in all replicates, n = 4).
The major mechanical response to B 1 R stimulation in the rabbit isolated aorta, contraction, is opposed to the relaxation observed in the mesenteric artery. To ascertain that the different experimental procedures do not determine these conclusions, aortic ring precontracted with phenylephrine were stimulated with des-Arg 9 -BK at the contraction plateau ( fig. 4A ). Only an additional contractile response to the kinin superimposed to the plateau was observed; adding 
Discussion
The present experiments provide evidence that Compound 11 is an exceptionally potent antagonist, with strong effects as a B 1 R antagonist at a concentrations as low as 100 pM (contractility, ERK1/2 phosphorylation, B 1 R-YFP translocation assays). This affinity surpasses that of the alternate nonpeptide B 1 R antagonist SSR 240612 by about 1 log unit in the rabbit aorta contractility assay (pA 2 9.4; Gougat et al., 2004) ; on the other hand, the latter drug is more potent at rodent B 1 Rs than Compound 11 (Su et al., 2003) , illustrating again the species-specific pharmacological divergences observed for a number of kinin receptor antagonists (Marceau et al., 1998; Burgess et al., 2000) . Compound 11 is active as an apparently surmountable antagonist of des-Arg 9 -BK or Lys-des-Arg 9 -BK in the rabbit aorta, but the Schild regression slope is significantly inferior to 1, a finding usually interpreted as lack of competitive behavior. However, a progressive increase of B 1 R agonist maximal effect has been observed in this preparation , a phenomenon attributed to the post-isolation formation of these receptors (Sabourin et al., 2002b) . This influx of novel surface receptors has been shown to distort the evaluation of both the potency and the competitive behavior of peptide B 1 R antagonists in this preparation . Nevertheless, the pA 2 estimate of 10.4-10.6 for Compound 11 is congruent with the K i values of 22-50 pM against cloned rabbit B 1 Rs (Su et al., 2003; present results based on myc-B 1 R).
Compound 11 also inhibited the biphasic effect of des-Arg 9 -BK on the precontacted mesenteric artery ( fig. 3 ). It was known that the COX inhibitor indomethacin reversed the relaxation into a superimposed contraction (Churchill and Ward, 1986; Deblois and Marceau, 1987) in this system, and that the difference between the rabbit isolated aorta and mesenteric artery is that the This article has not been copyedited and formatted. The final version may differ from this version. Levesque et al., 1993) . However, indomethacin does not influence the contractile effect of the kinin in this system, consistent with the ideas that the aorta is refractory to relaxant PGs, but that the B 1 R is efficiently coupled to PG synthesis. The pharmacological approach applied in present experiments shows that both COX-1 and -2 isoforms may participate to PG production controlled by the B 1 R, thus that the inducible COX-2 molecule can work in concert with the inducible B 1 R in a simulated inflammatory condition. The inflamed tissues is a plausible mechanism of the analgesic effect of B 1 R antagonists in animal models (Perkins et al., 1993) , especially for peptide antagonists with little central nervous system penetration. It remains to be determined whether a more lipophilic drug will influence pain perception in a different manner by both a central and a peripheral effect.
Tested as an antagonist of other receptors expressed in rabbit vascular smooth muscle, This article has not been copyedited and formatted. The final version may differ from this version. (Menke et al., 1994) . Such a high degree of selectivity for Compound 11 effect on kinin receptor subtypes is a practical advance over some recently developed peptide B 1 R antagonists (e.g., B-9858) which also antagonize the B 2 R with a ~200-fold selectivity for the B 1 R . Su et al. (2003) noted that Compound 11 exhibits a >5000-fold selectivity for the B 1 R in a panel of assays representing hundreds of enzymes, receptors and transporters, significantly better than the reported ~750-fold selectivity for the human B 1 R over the human B 2 R for the other nonpeptide SSR240612 (Gougat et al., 2004) . Compound 11 failed to antagonize EGF-induced ERK1/2 phoshorylation in rabbit aortic smooth muscle cells, implying that the drug is not an antagonist of EGF, an inhibitor of the EGF receptor tyrosine kinase activity or of any further enzyme that links the receptors to the MAP kinase activation.
The mechanisms of B 1 R coupling to the ERK1/2 MAP kinase pathway has not been fully elucidated, but it was observed in inflamed nasal mucosa tissue removed from human allergic patients challenged with Lys-des-Arg 9 -BK, not in tissue from healthy volunteers (Chistiansen et al., 2002) . In that report, the B 1 R-ERK1/2 coupling was speculatively linked to gene expression via the activation of the transcription factor AP-1.
The myc-labeled B 1 R was documented to conserve its pharmacological properties (affinity, profile), relative to the wild type receptor. Compound 11 is presumably cell permeant, but did not importantly influence myc-B 1 R abundance at the cell surface; thus, such high affinity antagonists may not always act as a "pharmacological chaperone". This property may apply to some, but not all antagonists for peptide hormone receptors (Morello et al., 2000; Petäjä-Repo et al., 2002) .
These considerations may be important for the safety of drugs, as a form of antagonist-induced receptor upregulation followed by metabolic drug disposition could theoretically exacerbate a pathology associated with this receptor. Chaperone-induced supersensitivity would represent an alternative to the situation where agonist-induced down-regulation is significant and chronic deprivation of receptor stimulation by antagonists leads to supersensitivity and receptor upregulation (e.g., as for the dopamine D 2 receptor blockers, Silvestri et al., 2000) . Agonistinduced downregulation is difficult to observe with recombinant kinin receptors (Houle et al., 2003) . A positive feedback mechanism where kinin receptor stimulation determines further B 1 R expression (the "autoregulation hypothesis", Schanstra et al., 1998; Phagoo et al., 1999 ) is controversial and may not be widely applicable (Sabourin et al., 2001; 2002b) . See text for analysis. Each experiment was performed at least twice using tissues from different animals. . . This article has not been copyedited and formatted. The final version may differ from this version.
